Home › Lung Diseases › NCT06775106

Exhaled Breath: A Novel Technique for Rapid Diagnosis of Respiratory Diseases and Infections

Who can join

Ages 18 to 120 · All sexes

Inclusion Criteria:

* Non-COVID-19 adult consented patients (\>18yo) on ventilatory support in the ICU at OHSU

Exclusion Criteria:

* Patients with "severe respiratory distress" as defined by arterial pO2 of \<60 mmHg on maximal FiO2 \& optimal ventilator settings
* Patient with severe hemodynamic instability as defined by (a) receiving IV infusion of 2 or more pressors or inotropic medications (Levophed, vasopressin, phenylephrine, or epinephrine) \& (b) MAP of \<60 mmHg or SB \<80 mmHg

About the study

This study aims to use mass spectrometry techniques to analyze exhaled patient breath in non-COVID ICU-admitted patients requiring ventilation for a rapid and accurate early detection of pulmonary diseases and inflammatory markers.

What is being tested

• There is no intervention in this observational study (other)

Sponsor: Oregon Health and Science University · Participants: 100 · Started: Nov 30, 2024

Contact the study team

• Laura H Nguyen, B.S. · Phone: 503-418-4733
• Albert Chi, M.D., F.A.C.S · Phone: 503-494-5300

Official record on ClinicalTrials.gov — NCT06775106

Locations in the U.S.

Conditions

• Lung Diseases
• Critical Illness

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.